{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:10:12Z","timestamp":1785510612732,"version":"3.56.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.yrtph.2026.106173","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:13:29Z","timestamp":1783178009000},"page":"106173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cardiovascular toxicity as a globally harmonized system hazard trait: The evidence and the path forward"],"prefix":"10.1016","volume":"171","author":[{"given":"Ivan","family":"Rusyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Tsitsimpikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn T.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Kleinstreuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106173_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.vascn.2016.12.003","article-title":"A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes","volume":"84","author":"Ando","year":"2017","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2026.106173_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2020.104916","article-title":"An integrated chemical environment with tools for chemical safety testing","volume":"67","author":"Bell","year":"2020","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.yrtph.2026.106173_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2024.1352783","article-title":"Challenging the status quo: a framework for mechanistic and human-relevant cardiovascular safety screening","volume":"6","author":"Berridge","year":"2024","journal-title":"Front Toxicol."},{"key":"10.1016\/j.yrtph.2026.106173_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.yrtph.2012.09.007","article-title":"Integrated and translational nonclinical in vivo cardiovascular risk assessment: gaps and opportunities","volume":"65","author":"Berridge","year":"2013","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106173_bib7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/cpt.1259","article-title":"Thorough QT\/QTc in a dish: an in vitro human model that accurately predicts clinical Concentration-QTc relationships","volume":"105","author":"Blanchette","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2026.106173_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/toxsci\/kfaa151","article-title":"A Bayesian method for population-wide cardiotoxicity hazard and risk characterization using an in vitro human model","volume":"178","author":"Blanchette","year":"2020","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2026.106173_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2022.107154","article-title":"A tiered approach to population-based in vitro testing for cardiotoxicity: balancing estimates of potency and variability","volume":"114","author":"Blanchette","year":"2022","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2026.106173_bib8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1161\/CIRCRESAHA.123.323613","article-title":"Environmental impacts on cardiovascular health and biology: an overview","volume":"134","author":"Blaustein","year":"2024","journal-title":"Circ. Res."},{"key":"10.1016\/j.yrtph.2026.106173_bib11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/toxsci\/kfw200","article-title":"Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias","volume":"155","author":"Blinova","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2026.106173_bib9","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","article-title":"International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment","volume":"24","author":"Blinova","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.yrtph.2026.106173_bib10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cts.12674","article-title":"Clinical trial in a dish: personalized stem cell-derived cardiomyocyte assay compared with clinical trial results for two QT-Prolonging drugs","volume":"12","author":"Blinova","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.yrtph.2026.106173_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114711","article-title":"Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes","volume":"381","author":"Burnett","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106173_bib12","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1021\/acs.chemrestox.1c00203","article-title":"Cardiotoxicity hazard and risk characterization of ToxCast chemicals using human induced pluripotent stem cell-derived cardiomyocytes from multiple donors","volume":"34","author":"Burnett","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106173_bib13","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/17425255.2021.1894122","article-title":"Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization","volume":"17","author":"Burnett","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106173_bib15","first-page":"359","article-title":"Ready for regulatory use: NAMs and NGRA for chemical safety assurance","volume":"39","author":"Carmichael","year":"2022","journal-title":"ALTEX"},{"key":"10.1016\/j.yrtph.2026.106173_bib16","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","article-title":"Global burden of cardiovascular diseases: projections from 2025 to 2050","volume":"32","author":"Chong","year":"2025","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.yrtph.2026.106173_bib17","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1073\/pnas.1221823110","article-title":"Profile of John Gurdon and Shinya Yamanaka, 2012 Nobel laureates in medicine or physiology","volume":"110","author":"Colman","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.yrtph.2026.106173_bib18","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/S0140-6736(25)00990-0","article-title":"The changing spectrum of cardiovascular diseases","volume":"406","author":"Conrad","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.yrtph.2026.106173_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.105026","article-title":"Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients","volume":"125","author":"Dent","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106173_bib20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s11239-020-02299-x","article-title":"Cellular model systems to study cardiovascular injury from chemotherapy","volume":"51","author":"Fonoudi","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.yrtph.2026.106173_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2024.153763","article-title":"Hazard and risk characterization of 56 structurally diverse PFAS using a targeted battery of broad coverage assays using six human cell types","volume":"503","author":"Ford","year":"2024","journal-title":"Toxicology"},{"key":"10.1016\/j.yrtph.2026.106173_bib22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/jcdd9070226","article-title":"Cardiotoxicity of chemical substances: an emerging hazard class","volume":"9","author":"Georgiadis","year":"2022","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.yrtph.2026.106173_bib23","doi-asserted-by":"crossref","DOI":"10.1289\/EHP7600","article-title":"Risk characterization and probabilistic concentration-response modeling of complex environmental mixtures using new approach methodologies (NAMs) data from organotypic in vitro human stem cell assays","volume":"129","author":"Hsieh","year":"2021","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.yrtph.2026.106173_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2024.124360","article-title":"Cardiovascular toxic effects of nanoparticles and corresponding molecular mechanisms","volume":"356","author":"Huang","year":"2024","journal-title":"Environ. Pollut."},{"key":"10.1016\/j.yrtph.2026.106173_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/adt.2017.786","article-title":"High-content assay multiplexing for vascular toxicity screening in induced pluripotent stem cell-derived endothelial cells and human umbilical vein endothelial cells","volume":"15","author":"Iwata","year":"2017","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.yrtph.2026.106173_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2024.1285768","article-title":"Comprehensive mapping of the AOP-Wiki database: identifying biological and disease gaps","volume":"6","author":"Jaylet","year":"2024","journal-title":"Front Toxicol."},{"key":"10.1016\/j.yrtph.2026.106173_bib27","first-page":"261","article-title":"Workflow for defining reference chemicals for assessing performance of in vitro assays","volume":"36","author":"Judson","year":"2019","journal-title":"ALTEX"},{"key":"10.1016\/j.yrtph.2026.106173_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/acs.chemrestox.0c00382","article-title":"High-Throughput screening to identify chemical cardiotoxic potential","volume":"34","author":"Krishna","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106173_bib29","series-title":"Multiscale modeling identifies cardiovascular risk from common chemical exposures","author":"Krishna","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106173_bib30","doi-asserted-by":"crossref","DOI":"10.1289\/EHP9321","article-title":"Key characteristics of cardiovascular toxicants","volume":"129","author":"Lind","year":"2021","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.yrtph.2026.106173_bib31","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/med.21476","article-title":"Comprehensive review of cardiovascular toxicity of drugs and related agents","volume":"38","author":"Mlad\u011bnka","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.yrtph.2026.106173_bib32","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/cvr\/cvaf119","article-title":"A comprehensive review\/expert statement on environmental risk factors of cardiovascular disease","volume":"121","author":"Munzel","year":"2025","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.yrtph.2026.106173_bib33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/CIRCRESAHA.119.315378","article-title":"Workshop report: FDA workshop on improving cardiotoxicity assessment with human-relevant platforms","volume":"125","author":"Pang","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.yrtph.2026.106173_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/toxsci\/kfaf019","article-title":"Integration of new approach methods for the assessment of data-poor chemicals","volume":"205","author":"Paul Friedman","year":"2025","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2026.106173_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2024.107511","article-title":"Collaborative science in action: a 20 year perspective from the Health and Environmental Sciences Institute (HESI) Cardiac Safety Committee","volume":"127","author":"Pierson","year":"2024","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2026.106173_bib36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12872-025-05156-y","article-title":"Derivation of ultrasound and electrocardiogram cardiac reference ranges for Mus musculus using the collaborative cross and identification of new cardiac models","volume":"25","author":"Popp","year":"2025","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.yrtph.2026.106173_bib37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1289\/ehp.1509912","article-title":"Key characteristics of carcinogens as a basis for organizing data on mechanisms of carcinogenesis","volume":"124","author":"Smith","year":"2016","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.yrtph.2026.106173_bib38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/rtph.2001.1493","article-title":"IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis","volume":"34","author":"Sonich-Mullin","year":"2001","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106173_bib39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2026.106173_bib40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.14573\/altex.1803011","article-title":"The US Federal Tox21 Program: a strategic and operational plan for continued leadership","volume":"35","author":"Thomas","year":"2018","journal-title":"ALTEX"},{"key":"10.1016\/j.yrtph.2026.106173_bib41","article-title":"The promise of animal testing alternatives at the U.S. food and drug administration and national institutes of health","volume":"3","author":"Tieghi","year":"2025","journal-title":"Nejm Ai"},{"key":"10.1016\/j.yrtph.2026.106173_bib42","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1021\/acs.chemrestox.4c00193","article-title":"Informing hazard identification and risk characterization of environmental chemicals by combining transcriptomic and functional data from human-induced pluripotent stem-cell-derived cardiomyocytes","volume":"37","author":"Tsai","year":"2024","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106173_bib43","series-title":"Guidelines for Carcinogen Risk Assessment. Risk Assessment Forum","year":"2005"},{"key":"10.1016\/j.yrtph.2026.106173_bib44","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/toxsci\/kfu199","article-title":"Adverse outcome pathway (AOP) development I: strategies and principles","volume":"142","author":"Villeneuve","year":"2014","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2026.106173_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1213959","article-title":"Building blocks of microphysiological system to model physiology and pathophysiology of human heart","volume":"14","author":"Vuorenpaa","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.yrtph.2026.106173_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2018.06.005","article-title":"CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion","volume":"93","author":"Wallis","year":"2018","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2026.106173_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/toxsci\/kfac095","article-title":"Use of human iPSC-CMs in nonclinical regulatory studies for cardiac safety assessment","volume":"190","author":"Yang","year":"2022","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2026.106173_bib48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.18609\/cgti.2020.012","article-title":"Vascular microphysiological systems to model diseases","volume":"6","author":"Zhang","year":"2020","journal-title":"Cell Gene Ther. Insight."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:36:32Z","timestamp":1785508592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026001467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":48,"alternative-id":["S0273230026001467"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106173","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular toxicity as a globally harmonized system hazard trait: The evidence and the path forward","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106173"}}